PBAC's latest decision on Influenza vaccine, adjuvanted: Noted (2019). Considered for Active immunisation against influenza in adults aged 65 years and above. The submission sought listing of both an adjuvanted trivalent influenza vaccine (aTIV/Fluad) at an increased price and an adjuvanted quadrivalent influenza vaccine (aQIV/Fluad Quad) on the National Immunisation Program.
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Adults aged ≥65 years for vaccination against influenza
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Immunogenicity
Pivotal trial size
1,778 patients
Key trials
V118_20, LIVE study (Mannino 2012, Villa 2013), Gravenstein 2018
Comparator
aTIV (Fluad) compared to non-adjuvanted QIVs (Afluria Quad, FluQuadri, Fluarix Tetra); aQIV (Fluad Quad) compared to aTIV (Fluad)
Economic model
Cost-minimisation
ICER note
Cost-minimisation basis for aTIV (March 2018); economic model details for current submission not fully detailed in available text.